We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Miscellaneous

Evolution Biotechnologies

Status: Expired

Sep 28th 2020 - Nov 5th 2020

Evolution Biotechnologies (EB) is a company that aims to bring technologies of biological control from their proven uses in agriculture into high-need and high-value biomedical markets. The company aims to curtail the spread of the house dust mite, a key cause of asthma, through its patented device. Its room treatment kit for domestic or commercial use contains natural agents that target the house dust mite in a highly specific way. The company anticipates that this method will be able to exert widespread, stable control across a whole room from limited initial applications, following a standard agricultural practice. EB expects a potential market size of $2 billion per annum in China, the UK, Europe, and the United States for its product. It is seeking an investment of £2 million to bring the aforementioned product to field trials.

read more read less

Evolution Biotechnologies Rating Review

Pitch rating powered by CROWDRATING

Rated on 07/10/2020

Pitch Rated

48%

Insufficient Data

Management

87%

Product

57%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £5,000,000
    pre-money valuation

    4.90%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    09473027
    company number

    Active
    company status

    05/03/2015
    incorporated 9 years

    £0.19
    share price

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 91%
Evolution Biotechnologies' team is relatively small, consisting of the CEO/CSO, COO and CBO. The team is led by the CEO/CSO who is skilled in Molecular Virology, Infectious Disease, Microbiology, Molecular Biology, Biotechnology, and Genomics. The company has not appointed a Product Developer and the responsibility for the same lies with the CEO. Their COO is skilled in Communications, Decision Making, Mergers and Acquisition, Startups, Problem Solving, and Negotiations. The company finances are overseen by their CBO who is specialised in Venture Capitalist, Corporate Finance, Private Equity, Strategic Planning, and Commercialization.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £5,000,000
    pre-money valuation

    4.90%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    09473027
    company number

    Active
    company status

    05/03/2015
    incorporated 9 years

    £0.19
    share price

  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph